Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21716818 | 0.93 | GSR (0.36) | GSRMAPTMEN1GAAKMT2A | |
| SCHEMBL21716903 | 0.93 | GSR (0.33) | GSRTDP1NPC1ALDH1A1LMNA | |
| SCHEMBL21716239 | 0.92 | PTGES (0.34) | GSRNPC1ALDH1A1LMNAMAPT | |
| SCHEMBL21716957 | 0.91 | GSR (0.39) | GSRSMN1; SMN2MEN1GAAKMT2A | |
| SCHEMBL21717019 | 0.90 | TDP1 (0.33) | GSRTDP1MEN1GAAKMT2A | |
| SCHEMBL21716696 | 0.87 | ALOX5 (0.32) | — | |
| SCHEMBL21716694 | 0.87 | ALOX5 (0.30) | — | |
| SCHEMBL21716819 | 0.87 | GSR (0.36) | GSRTDP1ALDH1A1LMNAMEN1 | |
| SCHEMBL21716265 | 0.85 | GSR (0.39) | GSRTDP1ALDH1A1MEN1GAA | |
| SCHEMBL21716460 | 0.85 | GSR (0.37) | GSRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192884-B2 | Heterocyclic compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2021-12-07 | — | — | US | disclosed |
| US-20200048226-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192884-B2 | Heterocyclic compound and organic light-emitting device comprising same | CYP1A1, CYP1B1, CRY1 | GSR 3951/4885TDP1 1382/4885NPC1 2005/4885 |
| US-20200048226-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CYP1A1, CYP1B1, CRY1 | GSR 3951/4885TDP1 1382/4885NPC1 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.